Discover important updates on product innovations, industry insights, and press coverage.
TRV-01 is the only technology designed to address the root causes of diabetic foot disease.
Stay up to date on our latest news & events.
With Blanca Segura, PhD, CEO & Co-Founder of Triovance
Triovance, one of eight private company finalists in the highly competitive.
Triovance has been selected for the INCIDE Pharma & Healthtech Booster Program
Company is on track to move into the clinic with TRV-01, a genetically modified cellular dressing.
Triovance is honored to be presenting at the Startup Spotlight of the 26th American Society of Gene and Cell Therapy
This study evaluated a novel skin graft (TRV-01) developed to improve the wound healing process in a glycated microenvir
Explore our collection of 200+ Premium Webflow Templates